Pfizer Inc., of New York, reported top-line results from a phase IIIB study evaluating the 24-month efficacy of Genotropin (somatropin) on the height in small-for-gestational-age children 24-30 months old. The primary endpoint of the 39-patient study was achieved: There was a statistically significant difference at 24 months in change from baseline height between patients treated with Genotropin and those in the untreated control group, as measured by height standard deviation score.